Canlitinib
Product Specifications
UNSPSC Description
Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study.
Target Antigen
c-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/canlitinib.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CCCCCOC1=CC2=NC=CC(OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(C=C5)F)=O)=O)C=C3F)=C2C=C1OC)O
Molecular Weight
619.61
References & Citations
[1]Zhang, Zhiqiang, et al. Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof. WO2017-CN104518
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-156603/Canlitinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-156603/Canlitinib-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2222730-78-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1049499-01 0.02 mg (E-Coli)
Recombinant Escherichia coli O1:K1 / APEC ADP-L-glycero-D-manno-heptose-6-epimerase (hldD)
Ask
View Details